At a glance
ClinicalIndex Comparison RecordPhase 2Active· 41 target
Drug / intervention
Camrelizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SBRT Combined With Programmed Death 1 (PD-1) Antibody and Chemotherapy in Nasopharyngeal Carcinoma With Oligometastasis: A Prospective, Multicenter, Single-arm, Phase II Clinical Trial
In Brief
A Phase 2 clinical trial evaluating SBRT, Camrelizumab, and 2 other interventions for Nasopharyngeal Carcinoma. Active but no longer recruiting, targeting 41 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Timeline
Phase 2Active
20232024202520262027
First PostedSep 2022
Enrollment StartNov 2022
Primary CompletionJun 2025
TodayJul 2026
Study CompletionDec 2026
First PostedSep 1, 2022
Enrollment StartNov 25, 2022
Primary CompletionJun 6, 2025
Study CompletionDec 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 3.8 years ago
Interventions
SBRTradiation
SBRT for metastatic lesions
Camrelizumabdrug
Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.
Gemcitabinedrug
Maximum 6 cycles for combined therapy.
Cisplatindrug
Maximum 6 cycles for combined therapy.